Evidence map›Paper›PMID 27066155›Full record

ArticleCognitive neurodynamics2016

Effect of high dose cytosine arabinoside on quantitative EEG in patients with acute myeloid leukemia.

Marta Maschio, Francesco Marchesi, Sabrina Dispenza, Loredana Dinapoli, Francesca Sperati, Gianluca Petreri, Svitlana Gumenyuk, Maria Laura Dessanti, Alessia Zarabla, Tonino Cantelmi and 1 more

Open access · bronzeAbstract read
In one paragraph

Article in Cognitive neurodynamics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Marta MaschioCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Francesco MarchesiHematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Sabrina DispenzaCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Loredana DinapoliCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Francesca SperatiBiostatistics/Scientific Direction, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Gianluca PetreriCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Svitlana GumenyukHematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Maria Laura DessantiHematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Alessia ZarablaCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Tonino CantelmiCenter for Tumor-Related Epilepsy, Area of Supporting Care, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
Andrea MengarelliHematology and Stem Cell Transplantation Unit, Regina Elena National Cancer Institute, Via Elio Chianesi, 53, 00144 Rome, Italy.
National Cancer Institute · MY

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background EEG activity is considered an index of functional state of brain. Chemotherapy (CT), used for non-central nervous system (CNS) cancer, can cross the blood brain barrier and contribute to changes in the functional state of brain that can alter background EEG activity. Quantitative EEG (qEEG) is superior to conventional EEG in the detection of subtle alterations of EEG background activity and for this reason, the use of qEEG might assist the clinician in evaluating the possible effect of CT on the CNS. The nucleoside analog cytosine arabinoside (Ara-C) is one of the milestone chemotherapeutic agents used for treatment of acute myeloid leukemia (AML). Our observational study evaluates the possible effect of Ara-C on the qEEG of patients with AML, without CNS involvement. We conducted an observational study on newly diagnosed AML patients without CNS involvement, undergoing treatment with Ara-C to analyze the possible effect of Ara-C high doses on EEG background activity using qEEG analyses. A total of nine AML patients, 5 with Ara-C i.v. high dose (≥3 g/m(2) die), 4 with standard dose (100 mg/m(2) die) underwent qEEG (at rest, during hyperpnoea, mental arithmetic task and blocking reaction). We compared the EEG background activity of the two groups at baseline and after 6 months. Statistical analysis showed no significant differences between the two groups in mean relative power for all frequency bands, at rest and during hyperpnoea, mental arithmetic task and blocking reaction. Our data indicate that high dose Ara-C i.v. did not induce significant changes on EEG background activity in our patients. Future research in this area could include prospective studies that would combine qEEG and neuropsychological testing to assess the impact of CT on brain functions.

Indexed as

Acute myeloid leukemiaCNSHigh dose cytosine arabinosideqEEG

Identifiers

PMID27066155
PMCPMC4805690
OpenAlexW2238217157

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.